Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2

MLA

Reshma Mahtani, et al. “Efficacy and Safety of Palbociclib in Patients with Estrogen Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2.” Breast, vol. 59, Oct. 2021, pp. 321–26. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0104cae2c0a2c79565e498e192266c5c&authtype=sso&custid=ns315887.

APA

Reshma Mahtani, Janice M. Walshe, Eustratios Bananis, Meghan Sri Karuturi, D. Lu, Sindy T. Kim, Patrick Schnell, Anil A. Joy, Karen A. Gelmon, Patrick Neven, & Lee S. Schwartzberg. (2021). Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2. Breast, 59, 321–326.

Chicago

Reshma Mahtani, Janice M. Walshe, Eustratios Bananis, Meghan Sri Karuturi, D. Lu, Sindy T. Kim, Patrick Schnell, et al. 2021. “Efficacy and Safety of Palbociclib in Patients with Estrogen Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2.” Breast 59 (October): 321–26. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0104cae2c0a2c79565e498e192266c5c&authtype=sso&custid=ns315887.